The dPCR market is anticipated to grow from US$ 7.52 billion in 2024 to US$ 14.34 billion by 2031; the market is expected to register a CAGR of 9.4% from 2025 to 2031. The dPCR Market growth is attributed to the demand for highly sensitive and accurate nucleic acid detection, expanding applications in clinical diagnostics and personalized medicine, and rising advancements in dPCR technology and automation.

Digital PCR (dPCR) is an advanced molecular biology technique used to precisely quantify DNA or RNA molecules. Unlike traditional PCR, which measures amplification in bulk, dPCR partitions a sample into thousands of tiny reactions, with each partition analyzed individually. By counting the number of positive reactions, it provides absolute quantification without the need for standard curves, making it highly sensitive for detecting low-abundance or rare genetic targets. dPCR is widely used in clinical diagnostics, infectious disease detection, oncology, forensics, and research, offering superior precision, reproducibility, and the ability to analyze degraded or complex samples that traditional PCR struggles with.

The dPCR Market in North America is segmented into the US, Canada, and Mexico. The growth of the US digital PCR Market is largely attributed to the increasing demand for precise and sensitive diagnostic tools in various medical fields. According to the Centers for Disease Control and Prevention (CDC), the prevalence of infectious diseases, including COVID-19, continues to drive the need for advanced testing methods, with diagnostic test volumes soaring from 200 million in 2022 to an estimated 250 million in 2023. As the CDC projects an enduring need for high-quality diagnostics, particularly in the detection of viral RNA and genetic mutations, dPCR technology has gained prominence for its enhanced specificity and sensitivity. Additionally, new product developments have contributed to market growth; for instance, in 2023, the US Food and Drug Administration (FDA) approved several novel dPCR assays for oncology, enabling earlier detection of cancers through liquid biopsy techniques. Furthermore, a study by the National Cancer Institute reported that, by 2024, ~1.9 million new cancer cases are expected to be diagnosed, fueling the demand for accurate molecular diagnostics in oncology.

Expansion into Microbial and Public Health Surveillance to Provide Market Opportunities in Future

Expansion into microbial and public health surveillance is a promising opportunity that lies in the expansion of dPCR into infectious disease surveillance and microbial diagnostics. In June 2024, QIAGEN launched 35 new wet-lab-tested microbial DNA detection assays on its QIAcuity platform, targeting pathogens including Dengue virus (serotypes 1-4), Monkeypox (clades I & II), malaria parasites, and antibiotic-resistance genes. These assays enhance the precision and sensitivity of pathogen quantification, enabling public-health labs to monitor outbreaks, track resistance, and respond more swiftly. These assays are available via QIAGEN's GeneGlobe portal, promoting broad access and ease of use. The ability of dPCR to provide absolute quantification without standard curves reduces variability and improves comparability between labs, which is crucial for coordinated surveillance programs. According to a review in The Journal of Applied Laboratory Medicine, clinical applications of dPCR include microbiology and infectious disease diagnostics, and the increasing portfolio of validated microbial assays lowers the barrier to clinical and public health adoption. As governments and international agencies increasingly prioritize genomic epidemiology, these developments create a strong opportunity for dPCR to become an integral tool in global health surveillance and outbreak response.

World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), American Chemical Society Publications, The U.S. Centers for Medicare & Medicaid Services (CMS), US Department of Health & Human Services, Public Health Agency of Canada (PHAC), French National Institute of Health and Medical Research (INSERM), Italian National Institute of Health (ISS), The Korean Journal of Internal Medicine, the Saudi Press Agency (SPA), UAE Ministry of Health and Prevention (MOHAP) are among the primary and secondary sources referred to while preparing the dPCR Market report.